Continuing bevacizumab with second-line chemotherapy for metastatic colorectal cancer prolongs survival

被引：0
|
作者：
不详
机构：
来源：
COLORECTAL CANCER | 2012年 / 1卷 / 04期
关键词：
D O I：
10.2217/CRC.12.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [1] Continuing bevacizumab with second-line chemotherapy for metastatic colorectal cancer prolongs overall and progression-free survival
    Williamson, Ruth
    [J]. IMMUNOTHERAPY, 2012, 4 (08) : 757 - 758
  • [2] Comparative analysis of the effectiveness of second-line bevacizumab plus chemotherapy in second-line therapy in metastatic colorectal cancer.
    Smagulova, Kaldigul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] Management of metastatic colorectal cancer and indications of second-line chemotherapy
    Rougier, PP
    [J]. PRESSE MEDICALE, 1996, 25 (22): : 1004 - 1005
  • [4] Survival predictors in second-line chemotherapy for metastatic gastric cancer
    Bohanes, P. O.
    Courvoisier, D.
    Perneger, T.
    Morel, P.
    Huber, O.
    Roth, A. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
    Shi, Sha
    Lu, Kemei
    Gao, Hui
    Sun, Huidong
    Li, Senlin
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1971 - 1977
  • [6] Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
    Claramunt Garcia, Raquel
    Munoz Cid, Carmen Lucia
    Sanchez Ruiz, Andres
    Marin Pozo, Juan Francisco
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (02) : 287 - 291
  • [7] Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer
    Todorovic, Vladimir
    Saric, Nada Cicmil
    Lakicevic, Jadranka
    Sorat, Milan
    [J]. JOURNAL OF BUON, 2017, 22 (05): : 1131 - 1136
  • [8] Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
    Raquel Claramunt García
    Carmen Lucía Muñoz Cid
    Andrés Sánchez Ruiz
    Juan Francisco Marín Pozo
    [J]. European Journal of Clinical Pharmacology, 2022, 78 : 287 - 291
  • [9] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer
    Yuki Matsubara
    Toshiki Masuishi
    Takatsugu Ogata
    Taiko Nakazawa
    Kyoko Kato
    Kazuki Nozawa
    Yukiya Narita
    Kazunori Honda
    Hideaki Bando
    Hiroya Taniguchi
    Shigenori Kadowaki
    Masashi Ando
    Masahiro Tajika
    Kei Muro
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1123 - 1129
  • [10] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Taniguchi, Hiroya
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1123 - 1129
12345